Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic

/PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that it...

Related Keywords

Sweden ,Czech Republic ,Prague ,Praha ,Hlavníesto ,Stockholm ,Jordan ,Czech ,Ondrej Viklicky ,Hansa Biopharma ,Prnewswire Hansa Biopharma ,Klaus Sindahl ,Head Transplant Center ,Institute For Clinical ,European Union ,Czech State Institute Of Drug ,European Medicines Agency ,Czech Coordination Centre For Transplantation ,European Medicines Agency Ema Priority ,Professor Ondrej Viklicky ,Experimental Medicine ,Human Leukocyte Antigens ,European Marketing Authorization ,End Stage Renal Disease ,Product Characteristics ,Nasdaq Stockholm ,Czech State Institute ,Drug Control ,Czech Coordination Centre ,Eurostam Report ,Dial Transplant ,Englj Med ,European Medicines ,Newsletter Transplant ,Hansa Biopharma Ab ,